Lanreotide and Octreotide Long Acting Release (LAR) for Patients With Advanced Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs)

Ipsen22 enrolled

Overview

An observational time and motion study in a clinical oncology setting is utilized in order to measure and compare product attributes and overall product efficiency between lanreotide and octreotide LAR.

Study Type

OBSERVATIONAL

Enrollment

Conditions

Gastroenteropancreatic Neuroendocrine Tumor

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Men and women must be 18 years of age or older * A current diagnosis of advanced, unresectable GEP-NET * Provided written informed consent to participate in the study * Currently receiving lanreotide or octreotide LAR and has received at least one prior injection of current somatostatin analogues (SSA). Exclusion Criteria: * Receiving treatment with lanreotide or octreotide LAR as part of a clinical trial * Scheduled to receive a dose of lanreotide or octreotide LAR that would necessitate more than 1 injection on the same day * Scheduled to receive any other treatment in the infusion center/room on the same day and as part of the same appointment * Known hypersensitivity to somatostatin analogues

Locations (5)

The University of Arizona Cancer Center

Tucson, Arizona, United States

Ochsner Medical Center Kenner

Kenner, Louisiana, United States

Mercy Medical Center

Baltimore, Maryland, United States

National Translational Research Group

East Setauket, New York, United States

Outcomes

Primary Outcomes

The total time for product preparation and administration

Total drug delivery time

Time frame: Day 1

Secondary Outcomes

Total patient wait time for administration

For the purposes of this study, "total patient wait time" refers to the time the patient checks in at the infusion room until completion of drug administration and discharge of the patient from the infusion room.

Time frame: Day 1

Number of clogging episodes

The number of clogging episodes for lanreotide and octreotide LAR will be recorded and compared.

Time frame: Day 1

Healthcare resource utilization

The materials used for the preparation of lanreotide and octreotide LAR will be recorded and compared.

Time frame: Day 1

Pharmacist and/or nurse satisfaction and product preference

Assessed by pharmacist and/or nurse completing questionnaire

Time frame: Day 1 and at the end of the study (approximately 3 months)

Patient satisfaction

Assessed by patient completing questionnaire

Time frame: Day 1

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.